|
 |
|
|||||||
|
|||||||||
Copyright ©ERS Journals Ltd 2008
Exhaled nitric oxide and asthma control: a longitudinal study in unselected patients
Chest Dept, Erasme University Hospital, Brussels, Belgium.
CORRESPONDENCE: A. Van Muylem, Chest Dept, CUB Erasme, 808 Route de Lennik, B-1070 Brussels, Belgium. Fax: 32 25554411. E-mail: avmuylem{at}ulb.ac.be
Keywords: Asthma control, exhaled nitric oxide, lung function
Received: February 19, 2007
Accepted October 31, 2007
Controlled studies have shown that monitoring of the exhaled nitric oxide fraction (FeNO) improves asthma management. However, the studies seldom consider the full range of patients seen in clinical practise. In the present study, the ability of FeNO to reflect asthma control over time is investigated in a regular clinical setting, and meaningful FeNO cut-off points and changes are identified.
Answers to the Asthma Control Questionnaire and FeNO were recorded at least once in 341 unselected asthma patients. The whole population and subgroups were considered, i.e. both inhaled corticosteroid (ICS)-naïve and low or high-to-medium (
An FeNO decrease <40% or increase <30% precludes asthma control optimisation or deterioration, respectively (negative predictive value 79 and 82%, respectively). In the present study’s low-dose group, a decrease >40% indicated asthma control optimisation (positive predictive value (PPV) 83%). In ICS-naïve patients, FeNO >35 ppb predicted asthma control improvement in response to ICS (PPV 68%). In most cases, forced expiratory volume in one second assessments were not useful.
In conclusion, in a given patient, exhaled nitric oxide fraction was found to be significantly related to asthma control over time. The overall ability of exhaled nitric oxide fraction to reflect asthma control was reduced in patients using high doses of inhaled corticosteroids. Forced expiratory volume in one second had little additional value in assessing asthma control.
or >500 µg beclomethasone dipropionate equivalents·day–1) ICS-dose groups.
This article has been cited by other articles:
|
|
 |
|
  H. K. Reddel, D. R. Taylor, E. D. Bateman, L.-P. Boulet, H. A. Boushey, W. W. Busse, T. B. Casale, P. Chanez, P. L. Enright, P. G. Gibson, et al. An Official American Thoracic Society/European Respiratory Society Statement: Asthma Control and Exacerbations: Standardizing Endpoints for Clinical Asthma Trials and Clinical Practice Am. J. Respir. Crit. Care Med., July 1, 2009; 180(1): 59 - 99. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P-R. Burgel, J. de Blic, P. Chanez, C. Delacourt, P. Devillier, A. Didier, J-C. Dubus, I. Frachon, G. Garcia, M. Humbert, et al. Update on the roles of distal airways in asthma Eur. Respir. Rev., June 1, 2009; 18(112): 80 - 95. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Michils, R. Louis, R. Peche, S. Baldassarre, and A. Van Muylem Exhaled nitric oxide as a marker of asthma control in smoking patients Eur. Respir. J., June 1, 2009; 33(6): 1295 - 1301. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D R Taylor Risk assessment in asthma and COPD: a potential role for biomarkers? Thorax, March 1, 2009; 64(3): 261 - 264. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. R. Taylor Exhaled Nitric Oxide: Still Alive, Not Laid to Rest Am. J. Respir. Crit. Care Med., January 15, 2009; 179(2): 88 - 89. [Full Text] [PDF]
|
|
|
|
 |
|
 D R Taylor and I D Pavord Biomarkers in the assessment and management of airways diseases Postgrad. Med. J., December 1, 2008; 84(998): 628 - 634. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Lopes, J. Fonseca, L. Delgado, A. Moreira, R. Barros, P. Moreira, and M. da G. Castelo-Branco Assessing asthma control: questionnaires and exhaled nitric oxide provide complementary information Eur. Respir. J., November 1, 2008; 32(5): 1419 - 1420. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |